Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

Casita Feliz, a nonprofit serving the Latino LGBTQ+ community in Fresno, recently celebrated its one-year anniversary ...

Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

The U.S. District Court for the Northern District of California ordered Lorik Papyan, who pleaded guilty three years ago to one count of unlicensed wholesale distribution of prescription drugs, to pay ...

75th Annual H-E-B Thanksgiving Day Parade Get into the holiday spirit at the 75th Annual Houston Thanksgiving Day Parade, a ...

In Uganda, women and girls are more affected by HIV. Out of 1.4 million people living with the disease, 860 000 are women and ...